SMSam Manna

Sam Manna

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sam Manna has a total of 121 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Epidemiological, immunological and virulence characteristics of persistent Streptococcus pneumoniae vaccine serotypes following vaccine introduction

    by Paige Skoko, Sam Manna, Laura K. Boelsen, Jason Hinds, Stephanie W. Lo, Casey L. Pell, Belinda D. Ortika, Rachel A. Higgins, Vicki Bennett-Wood, Hanwen Hou, et al.

    Streptococcus pneumoniae vaccine serotypes can persist despite pneumococcal conjugate vaccine (PCV) introduction. To examine serotype persistence, we leverage 6,545 nasopharyngeal swabs collected from children hospitalised with pneumonia before and after PCV13 introduction in Mongolia. DNA microarray was used to identify changes in lineage composition within serotypes 6A, 6B, 14, 19F and 23F over the six-year surveillance period. Children carrying post-PCV lineages are less likely to have severe pneumonia (serotypes 6B, 14 and 19F) and be multi-drug resistant (serotypes 6A, 6B and 23F) than pre-PCV lineages. Of note, the post-PCV lineage of serotype 6B has lower antibody binding to capsule and expression of capsule genes, thinner capsule and is less virulent in mice compared with the pre-PCV lineage. Our data show that although vaccine serotypes can persist in vaccinated populations, vaccination may select less virulent lineages within vaccine serotypes. Therefore, considering factors beyond serotype is important when evaluating the true value of vaccination.

  • Open Access

    SeroBA(v2.0) and SeroBAnk: a robust genome-based serotyping scheme and comprehensive atlas of capsular diversity in Streptococcus pneumoniae

    by Oliver Lorenz, Alannah C. King, Harry C. H. Hung, Feroze A. Ganaie, Anne L. Wyllie, Sam Manna, Catherine Satzke, Mark van der Linden, Neil Ravenscroft, Hans-Christian Slotved, et al.

    The unprecedented number of Streptococcus pneumoniae (the pneumococcus) genomes sequenced in recent years has accelerated the discovery of novel serotypes and highlighted the genetic diversity both between and within each serotype. A novel serotype should demonstrate a distinct cps locus, capsular structure and serological profile. In only the past 4 years, nine new serotypes have been identified. Accurate and timely serotyping of pneumococcal isolates is key to understanding their global distribution, evolution and the response of the bacterial population to vaccination. However, current bioinformatics serotyping tools are infrequently updated and struggle to accommodate the rapid discovery of new serotypes in a timely manner. To address these limitations, we built a comprehensive and curated library (SeroBAnk) encompassing all known pneumococcal serotypes; this resource is presented as an atlas on a dedicated publicly accessible webpage (https://www.pneumogen.net/gps/ #/serobank). Building upon this resource, we developed SeroBA(v2.0), a tool with an easy-to-update database that can accurately identify 102 of 107 known pneumococcal serotypes (except for serotypes 24B, 24C, 24F, 7D and 6H) and 18 genetic subtypes within serotypes 6A, 6B, 11A, 19A, 19F and 33F. We validated SeroBA(v2.0) on 26,306 genomes from the Global Pneumococcal Sequencing project, reference isolates and simulated reads derived from the reference genetic sequences of capsular polysaccharide biosynthetic (cps) locus. We showed that SeroBA(v2.0) can reliably detect the nine recently discovered serotypes. Additionally, we show that in silico serotypes inferred by SeroBA(v2.0) had high concordance with phenotypic serotypes determined by either Quellung or latex agglutination at the serotype level (88.9%; 15,945/17,933) and at the serogroup level (91.9%; 16,480/17,933). Finally, we propose a community-contribution-based approach to ensure that SeroBA(v2.0) is maintained and updated as novel serotypes continue to be discovered. The global community can submit putative novel serotypes through our public repository on GitHub (https://github.com/GlobalPneumoSeq/seroba/issues). The submitted putative novel serotypes will be curated based on the genetic sequence of the cps region, capsular structure and serological profile by people of relevant expertise in the field. SeroBA(v2.0) can be accessed at https://github.com/GlobalPneumoSeq/seroba .


  • Open Access

    Streptococcus pneumoniae vaccine serotype persistence following 13-valent pneumococcal conjugate vaccine introduction in Mongolia: investigating changes in epidemiology, immunology and virulence

    by Paige Skoko, Sam Manna, Laura K. Boelsen, Jason Hinds, Stephanie W. Lo, Casey L. Pell, Belinda D. Ortika, Rachel A. Higgins, Vicki Bennett-Wood, Hanwen Hou, et al.

    Background: Streptococcus pneumoniae is a leading cause of pneumonia globally. Vaccine serotypes can persist despite pneumococcal conjugate vaccine (PCV) introduction. To examine serotype persistence, we leveraged 6,545 nasopharyngeal swabs collected from children hospitalised with pneumonia before and after PCV13 introduction in Mongolia and undertook molecular, epidemiological and experimental analyses. Methods: Serotype, genetic lineage and antimicrobial resistance genes were inferred from DNA microarray. Patients carrying lineages that were predominant pre- and post-PCV introduction were examined for differences in disease severity. We also compared the pre- and post-PCV lineages by bacterial adhesion to hydrocarbon (BATH) and enzyme-linked immunosorbent (ELISA) assays. Capsule gene expression was measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR), capsule thickness by transmission electron microscopy, and virulence using an infant mouse model. Findings: Changes in lineage composition were observed within serotypes 6A, 6B, 14, 19F and 23F over the six-year surveillance period. Children carrying pre-PCV lineages were more likely to have severe pneumonia than those carrying post-PCV lineages (serotypes 6B, 14 and 19F). Pre-PCV lineages were more likely to be multi-drug resistant than post-PCV lineages (serotypes 6A, 6B and 23F). For serotype 6B the post-PCV lineage had higher cell surface hydrophobicity, lower IgG, lower expression of capsule genes and evidence of thinner capsule than the pre-PCV lineage. Notably, the post-PCV 6B lineage was also less virulent in mice than the pre-PCV 6B lineage. Interpretation: Despite persistence of vaccine serotypes in highly vaccinated populations, vaccination may select for lineages with differences in capsule and antibody binding and that are less virulent. When evaluating the true value of vaccination, it is important to consider factors beyond serotype alone. Funding: National Health and Medical Research Council, Murdoch Children’s Research Institute, GAVI, the Vaccine Alliance.

  • Open Access

    Streptococcus pneumoniae serotype 33H: a novel serotype with frameshift mutations in the acetyltransferase gene wciG

    by Sam Manna, Belinda D. Ortika, Joel P. Werren, Casey L. Pell, Ilche Gjuroski, Stephanie W. Lo, Jason Hinds, Odgerel Tundev, Eileen M. Dunne, Bradford D. Gessner, et al.

    Background: Streptococcus pneumoniae (the pneumococcus) is a leading cause of community-acquired pneumonia. Pneumococci are categorised into serotypes, based on the type of capsular polysaccharide produced, which has important implications for virulence, vaccine impact and global surveillance. Recently, we identified a novel serotype, which we named 33G, that is comprised of an O-acetylated hexasaccharide repeat unit. In this study, we report and describe variants of 33G, designated 33G-like, which we isolated from the nasopharynx of two adults hospitalised with pneumonia in Mongolia. Methods: Serological comparison of 33G and 33G-like pneumococci were conducted by Quellung serotyping. Genetic analysis of the capsular polysaccharide loci was performed using whole genome sequencing. Polysaccharide composition was determined using 1H nuclear magnetic resonance. Results: By Quellung serotyping, 33G pneumococci type as both 10B and 33B whereas 33G-like pneumococci type as both 10B and 33F. Genomic analysis of the capsular polysaccharide locus revealed 33G-like loci are identical to 33G, except for frameshift mutations in the wciG gene which encodes an acetyltransferase responsible for the O-acetylation of beta-galactofuranose (β-Galf) in the capsular polysaccharide repeat unit. We constructed an artificial 33G-like by deleting wciG in a 33G strain and confirmed this gene was responsible for the serological differences between 33G and 33G-like pneumococci. Lastly, 1H nuclear magnetic resonance confirmed the O-acetylation present in the 33G polysaccharide is absent in the 33G-like polysaccharide. Conclusions: Here, we have provided serological, genetic and biochemical evidence that the 33G-like capsule differs to 33G and all other pneumococcal serotypes, meeting the requirements to be designated as a new serotype, which we have named 33H.


  • Top Cited Papers

    Update on the evolving landscape of pneumococcal capsule types: new discoveries and way forward

    by Feroze A. Ganaie, Bernard W. Beall, Jigui Yu, Mark van der Linden, Lesley McGee, Catherine Satzke, Sam Manna, Stephanie W. Lo, Stephen D. Bentley, Neil Ravenscroft, et al.

    SUMMARY: Streptococcus pneumoniae (the “pneumococcus”) is a significant human pathogen. The key determinant of pneumococcal fitness and virulence is its ability to produce a protective polysaccharide (PS) capsule, and anti-capsule antibodies mediate serotype-specific opsonophagocytic killing of bacteria. Notably, immunization with pneumococcal conjugate vaccines (PCVs) has effectively reduced the burden of disease caused by serotypes included in vaccines but has also spurred a relative upsurge in the prevalence of non-vaccine serotypes. Recent advancements in serotyping and bioinformatics surveillance tools coupled with high-resolution analytical techniques have enabled the discovery of numerous new capsule types, thereby providing a fresh perspective on the dynamic pneumococcal landscape. This review offers insights into the current pneumococcal seroepidemiology highlighting important serotype shifts in different global regions in the PCV era. It also comprehensively summarizes newly discovered serotypes from 2007 to 2024, alongside updates on revised chemical structures and the de-novo determinations of structures for previously known serotypes. Furthermore, we spotlight emerging evidence on non-pneumococcal Mitis-group strains that express capsular PS that are serologically and biochemically related to the pneumococcal capsule types. We further discuss the implications of these recent findings on capsule nomenclature, pneumococcal carriage detection, and future PCV design. The review maps out the current status and also outlines the course for future research and vaccine strategies, ensuring a continued effective response to the evolving pneumococcal challenge.


  • Leveraging networks to provide guidance to early-career microbiologists: the Australian Society for Microbiology Mentoring Program

    by Priscilla Johanesen, Mark A Schembri, Dena Lyras, Sam Manna

    In Australia, most mentoring programs are organization-based, rather than discipline-based. To address the need to support our early career microbiologists, we leveraged the professional membership of the Australian Society for Microbiology (ASM) to develop and evaluate the performance of a mentoring program. The ASM Mentoring Program (ASMMP) was a national 6-month program in which 33 mentor–mentee pairs were matched and met monthly from June to December 2023. Over 80% of respondents agreed ASMMP was a beneficial, rewarding experience and would recommend the program to a colleague. Mentees reported a sense of improved career planning, networking skills, and a better working relationship with their line manager/supervisor. Most mentors reported a sense of fulfilment from being able to support and guide their mentee. Overall, ASMMP was a manageable and cost-effective strategy for the ASM to support the professional development of early career members while addressing an unmet mentoring need.


  • Open Access

    Streptococcus pneumoniae serotype 33G: genetic, serological, and structural analysis of a new capsule type

    by Sam Manna, Joel P. Werren, Belinda D. Ortika, Barbara Bellich, Casey L. Pell, Elissavet Nikolaou, Ilche Gjuroski, Stephanie Lo, Jason Hinds, Odgerel Tundev, et al.

    Streptococcus pneumoniae (the pneumococcus) is a human pathogen responsible for a spectrum of diseases such as pneumonia, sepsis, and meningitis. The capsule is the major pneumococcal virulence factor and is encoded by the capsular polysaccharide ( cps ) locus, a recombination hotspot that has resulted in over 100 distinct capsular polysaccharide types (serotypes) identified to date. Recently, 33X (also known as 10X) was proposed as a putative novel serotype, but the capsule structure had not been elucidated. Here, we provide an in-depth investigation of 33X, demonstrating it is a new pneumococcal capsular serotype. In this study, we screened 12,850 nasopharyngeal swabs from both healthy children and pneumonia patients (adults and children) in Mongolia collected between 2015 and 2022. We identified 20 pneumococcal 33X isolates. Using whole genome sequencing, we found that the 33X cps locus is a chimera of genes from pneumococcal serogroups 35, 10, and 33, as well as other Streptococcal species. Serotyping of 33X pneumococci by the Quellung reaction revealed a unique serological profile, typing as both 10B and 33B. Competitive ELISAs confirmed that antibodies that were generated in mice directed against 33X were inhibited by 33X pneumococci but not 10B or 33B. Lastly, the elucidation of the 33X capsule structure revealed that the polysaccharide is distinct from other serotypes, consisting of an O-acetylated hexasaccharide repeat unit of →5)-β-Gal f -(1→3)-β-Glc p -(1→5)-β-Gal f 2Ac-(1→3)-β-Gal p NAc-(1→3)-α-Gal p -(1→4)-Rib-ol-(5→P→. Therefore, 33X meets the requisite genetic, serological, and biochemical criteria to be designated as a new serotype, which we have named 33G. IMPORTANCE: Streptococcus pneumoniae (the pneumococcus) is a bacterial pathogen with the greatest burden of disease in Asia and Africa. The pneumococcal capsular polysaccharide has biological relevance as a major virulence factor as well as public health importance as it is the target for currently licensed vaccines. These vaccines have limited valency, covering up to 23 of the >100 known capsular types (serotypes) with higher valency vaccines in development. Here, we have characterized a new pneumococcal serotype, which we have named 33G. We detected serotype 33G in nasopharyngeal swabs ( n = 20) from children and adults hospitalized with pneumonia, as well as healthy children in Mongolia. We show that the genetic, serological, and biochemical properties of 33G differ from existing serotypes, satisfying the criteria to be designated as a new serotype. Future studies should focus on the geographical distribution of 33G and any changes in prevalence following vaccine introduction.


  • Open Access

    Streptococcus pneumoniae serotype 33G: genetic, serological, and structural analysis of a new capsule type

    by Sam Manna, Joel P. Werren, Belinda D. Ortika, Barbara Bellich, Casey L. Pell, Elissavet Nikolaou, Ilche Gjuroski, Stephanie W Lo, Jason Hinds, Odgerel Tundev, et al.

    Streptococcus pneumoniae (the pneumococcus) is a human pathogen responsible for a spectrum of diseases such as pneumonia, sepsis, and meningitis. The capsule is the major pneumococcal virulence factor and is encoded by the capsular polysaccharide ( cps ) locus, a recombination hot spot that has resulted in over 100 distinct capsular polysaccharide types (serotypes) identified to date. Recently, 33X (also known as 10X) was proposed as a putative novel serotype, but the capsule structure had not been elucidated. Here, we provide an in-depth investigation of 33X, demonstrating it is a new pneumococcal capsular serotype. In this study, we screened 12,850 nasopharyngeal swabs from both healthy children and pneumonia patients (adults and children) in Mongolia collected between 2015-2022. We identified 20 pneumococcal 33X isolates. Using whole genome sequencing, we found that the 33X cps locus is a chimera of genes from pneumococcal serogroups 35, 10 and 33, as well as other Streptococcal species. Serotyping of 33X pneumococci by the Quellung reaction revealed a unique serological profile, typing as both 10B and 33B. Competitive ELISAs confirmed that antibodies that were generated in mice directed against 33X were inhibited by 33X pneumococci but not 10B or 33B. Lastly, elucidation of the 33X capsule structure revealed that the polysaccharide is distinct from other serotypes, consisting of an O-acetylated hexasaccharide repeat unit of →5)-β-Gal f -(1→3)-β-Glc p -(1→5)-β-Gal f 2Ac-(1→3)-β-Gal p NAc-(1→3)-α-Gal p -(1→4)-Rib-ol-(5→P→. Therefore, 33X meets the requisite genetic, serological, and biochemical criteria to be designated as a new serotype, which we have named 33G. IMPORTANCE: Streptococcus pneumoniae (the pneumococcus) is a bacterial pathogen with the greatest burden of disease in Asia and Africa. The pneumococcal capsular polysaccharide has biological relevance as a major virulence factor, as well as public health importance as it is the target for currently licensed vaccines. These vaccines have limited valency, covering up to 23 of the >100 known capsular types (serotypes) with higher valency vaccines in development. Here, we have characterized a new pneumococcal serotype, which we have named 33G. We detected serotype 33G in nasopharyngeal swabs (n=20) from children and adults hospitalized with pneumonia, as well as healthy children in Mongolia. We show that the genetic, serological, and biochemical properties of 33G differs from existing serotypes, satisfying the criteria to be designated as a new serotype. Future studies should focus on the geographical distribution of 33G and any changes in prevalence following vaccine introduction.


  • Open Access

    Impact of COVID-19 Nonpharmaceutical Interventions on Pneumococcal Carriage Prevalence and Density in Vietnam

    by Monica Larissa Nation, Sam Manna, Hau Phuc Tran, Cattram Duong Nguyen, Le Thi Tuong Vy, Doan Y Uyen, Tran Linh Phuong, Vo Thi Trang Dai, Belinda Daniela Ortika, Ashleigh Christina Wee-Hee, et al.

    The pneumococcus is a major cause of mortality globally. Implementation of NPIs during the COVID-19 pandemic led to reductions in invasive pneumococcal disease in many countries.


  • Open Access

    Editorial: Thematic issue on bacterial–viral co-infections

    by Sam Manna, Daniel M Weinberger, Catherine Satzke

    Host and microbial factors are critically important for influencing the severity and outcome of infection. Interactions between microbes is an understudied yet important aspect to this process. Such interactions can include interplay of pathogens with members of the microbiome and/or other pathogens, which can play a major role in determining infectious disease severity (Neu and Mainou 2020). These interactions can be synergistic, resulting in enhanced disease severity, or antagonistic, whereby the presence of one microbe might be protective and reduce the risk of infection or disease severity caused by the infecting pathogen. This thematic issue for FEMS Microbes features a collection of papers that explore the microbiology and epidemiology of bacterial-viral co-infections, particularly Streptococcus pneumoniae (pneumococcus), influenza virus, and SARS-CoV-2.